IMARC Group

Smart cards are expected to change the lives of millions of people living in remote villages who have no access to any kind of financial services.

Excluding Mabthera, Roche’s other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020.

A New Report from IMARC Group expects the growth of the biosimilar market to expand the demand of cold chain logistic services in the coming years.

Despite a sluggish economic scenario, the expansion of new wind energy projects has so far continued unabated. A supply shortage of key raw materials, however, may jeopardize the growth of the entire industry.

India has historically lagged behind the west and other major Asian countries in the usage of smart cards. The country, however, is poised to enter a smart revolution or to make it more precise - a smart card revolution

Biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).

With billions of dollars at stake, Pfizer is doing its every bit to save Lipitor from a complete free-fall resulting from its patent expiry later this month.

With demand expected to significantly outpace supply in the coming years, India may not have enough milk to feed its own population - let alone feed others.

With the patents of all major monoclonal antibodies set to expire during 2015 - 2020, Biosimilar (or Follow-on) Monoclonal Antibodies are expected to represent the next big thing for generic manufacturers

Despite a recent bust, prospects for rare earth stocks will remain strong in the long term. Investors, however, will have to closely analyze the grade and composition of individual rare earths before investing in a mine.